𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks

✍ Scribed by M.E.R. O’Brien; J.S. Myerson; J.I.G. Coward; M. Puglisi; L. Trani; A. Wotherspoon; B. Sharma; G. Cook; S. Ashley; R. Gunapala; S. Chua; S. Popat


Book ID
116430925
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
270 KB
Volume
48
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.